Primary completion· ClinicalTrials.gov
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
Dapagliflozin History and Updates
250 events · 2002 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
477
FDA Approvals
91
Label Revisions
2,286
Trial Milestones
8
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-18Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Dapagliflozin since 2002, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (58)
2026
- Results postedDapagliflozin Reduces Systolic Blood Pressure in Kidney Transplant Recipients· Jun 8, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Risk Reduction in T2DM· May 27, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Risk Reduction in T2D Adults· May 18, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Hospitalization Risk Reduction· May 13, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Risk Reduction in T2DM· May 11, 2026
- Primary completionDapagliflozin Trial for Renal Protection in Heart Transplant Recipients…· Apr 30, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Hospitalization Risk Reduction· Apr 8, 2026
- FDA approvalDapagliflozin And Metformin Hydrochloride Gains Initial FDA Approval· Apr 6, 2026
- FDA approvalDapagliflozin And Saxagliptin Generic Approved by FDA· Apr 6, 2026
- FDA approvalDapagliflozin And Metformin Hydrochloride ANDA Approved by FDA· Apr 6, 2026
- FDA approvalFDA Approves Generic Dapagliflozin And Metformin Hydrochloride· Apr 6, 2026
- FDA approvalDapagliflozin and Metformin Hydrochloride Generic Approved by FDA· Apr 6, 2026
- FDA approvalDapagliflozin Gains Initial FDA Approval for Teva Pharmaceuticals· Apr 6, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Hospitalization Risk Reduction· Apr 6, 2026
- FDA approvalDapagliflozin Generic Approved by FDA on April 6, 2026· Apr 6, 2026
- FDA approvalDapagliflozin (Alembic) Gains Initial FDA Approval· Apr 6, 2026
- FDA approvalDapagliflozin and Metformin HCl Generic Approved by FDA· Apr 6, 2026
- FDA approvalDapagliflozin: FDA Approves Initial Generic Version from Ajanta Pharma· Apr 6, 2026
- FDA approvalFDA Approves Generic Dapagliflozin and Metformin Hydrochloride· Apr 6, 2026
- FDA approvalDapagliflozin Generic Approved by FDA for Zydus Pharmaceuticals· Apr 6, 2026
- FDA approvalFDA Approves Generic Dapagliflozin on April 6, 2026· Apr 6, 2026
- FDA approvalDapagliflozin Generic Approved by FDA on April 6, 2026· Apr 6, 2026
- FDA approvalDapagliflozin Generic from AIZANT Approved by FDA on April 6, 2026· Apr 6, 2026
- FDA approvalFDA Approves Generic Dapagliflozin from BIOCON PHARMA on April 6, 2026· Apr 6, 2026
- FDA approvalDapagliflozin Receives Initial FDA Approval as Generic on April 6, 2026· Apr 6, 2026
- FDA approvalDapagliflozin Generic Receives Initial FDA Approval· Apr 6, 2026
- FDA approvalDapagliflozin: FDA Approves First Generic Version from Macleods Pharma· Apr 6, 2026
- FDA approvalDapagliflozin Receives Initial FDA Approval for Generic Version· Apr 6, 2026
- FDA approvalDapagliflozin Receives Initial FDA Generic Approval on April 6, 2026· Apr 6, 2026
- Label revisionDapagliflozin Label Updated for Heart Failure Risk Reduction in T2D Adults· Apr 2, 2026
- Primary completionDapagliflozin Phase 3 Trial for Polycystic Ovary Syndrome Completes· Mar 30, 2026
- Primary completionDapagliflozin Trial for Type 2 Diabetes and CKD Completes Primary Phase· Mar 1, 2026
- Primary completionDapagliflozin Comparator Trial for Type 2 Diabetes Reaches Primary Completion· Feb 18, 2026
- Results postedDapagliflozin Vascular Health Trial for Type 2 Diabetes Terminated Early· Feb 11, 2026
- Primary completionDapagliflozin Trial for Breast Cancer Cardiotoxicity Reaches Primary Completion· Jan 30, 2026
- Results postedDapagliflozin Trial for Parkinson's, Lewy Body Dementia Shows MDS-UPDRS…· Jan 28, 2026
- Results postedDapagliflozin/Zibotentan Phase IIb in Cirrhosis Shows Fluid Retention· Jan 20, 2026
2025
- Label revisionDapagliflozin Label Updated for Heart Failure Risk Reduction in T2DM· Oct 31, 2025
- Results postedDapagliflozin Combination Shows Lower Mean Weight in Obesity, Pre-Diabetes, T2D· Oct 15, 2025
- Results postedDapagliflozin Shows No Significant Effect on Cystine Production in Cystinuria…· Oct 8, 2025
- Primary completionDapagliflozin Phase 3 Trial vs Orforglipron in Type 2 Diabetes Completes· Sep 26, 2025
- Primary completionDapagliflozin Trial for Acute Decompensated Heart Failure Reaches Primary…· Aug 1, 2025
- Primary completionDapagliflozin Phase 3 AKI Trial for Acute Kidney Injury Terminated· Jul 18, 2025
- Primary completionDapagliflozin Phase 3 Trial vs. HTD1801 in Type 2 Diabetes Completes Primary· Jun 13, 2025
- Primary completionDapagliflozin Phase 3 Trial for Chronic Kidney Disease Completes Primary Data…· May 31, 2025
- Results postedDapagliflozin Shows Higher Mean Renal Function in Lupus Nephritis Patients· Apr 16, 2025
- Primary completionDapagliflozin Phase 3 Trial for STEMI Myocardial Fibrosis Reaches Primary…· Mar 31, 2025
- Primary completionDapagliflozin Trial for Anterior STEMI Completes Primary Data Collection· Mar 15, 2025
- Results postedDapagliflozin Shows Superiority for Cardiometabolic Outcomes Post-Acute MI· Mar 7, 2025
- Pivotal publicationDapagliflozin Trial Results Published for Metabolic Dysfunction-Associated…· Jan 1, 2025
2024
- Primary completionDapagliflozin Reduces Blood Pressure in Kidney Transplant Recipients· Aug 30, 2024
- Pivotal publicationDapagliflozin DEFENDER Trial Results Published for Acute Organ Dysfunction· Jan 1, 2024
2022
- Pivotal publicationDapagliflozin Compared to Acetazolamide in Acute Decompensated Heart Failure· Jan 1, 2022
2021
- Pivotal publicationDapagliflozin: New Creatinine/Cystatin C GFR Equations Published Without Race· Jan 1, 2021
- Pivotal publicationDapagliflozin: Effects on Kidney Function in Advanced Chronic Kidney Disease· Jan 1, 2021
2020
- Pivotal publicationDapagliflozin: Meta-analysis shows SGLT2 inhibitor efficacy in HFrEF· Jan 1, 2020
- Pivotal publicationDapagliflozin's Effect on Worsening Heart Failure and CV Death Published in JAMA· Jan 1, 2020
- Pivotal publicationDapagliflozin: Cardiac Function Impact Post-MI in Non-Diabetic Patients· Jan 1, 2020
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients W
Primary completion· ClinicalTrials.gov
Effects of Dapagliflozin on Progression of Alport Syndrome
Primary completion· ClinicalTrials.gov
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
Primary completion· ClinicalTrials.gov
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
Primary completion· ClinicalTrials.gov
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Primary completion· ClinicalTrials.gov
The Fontan Dapagliflozin Pilot Study
Trial started· ClinicalTrials.gov
SGLT2i, Pioglitazone, and Ketone Production in T1D
Trial started· ClinicalTrials.gov
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
Primary completion· ClinicalTrials.gov
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy
Primary completion· ClinicalTrials.gov
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Primary completion· ClinicalTrials.gov
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Trial started· ClinicalTrials.gov
SGLT2i, Pioglitazone, and Ketone Production in T1D
Primary completion· ClinicalTrials.gov
Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)
Primary completion· ClinicalTrials.gov
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chroni
Primary completion· ClinicalTrials.gov
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
Trial started· ClinicalTrials.gov
DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Ty
Primary completion· ClinicalTrials.gov
Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty
Primary completion· ClinicalTrials.gov
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Primary completion· ClinicalTrials.gov
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Primary completion· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Trial started· ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Primary completion· ClinicalTrials.gov
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Pl
Primary completion· ClinicalTrials.gov
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Primary completion· ClinicalTrials.gov
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Primary completion· ClinicalTrials.gov
Dapagliflozin in Living-Donor Kidney Transplant Recipients
Trial started· ClinicalTrials.gov
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
Primary completion· ClinicalTrials.gov
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
Primary completion· ClinicalTrials.gov
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
Primary completion· ClinicalTrials.gov
Pilot Study on Evaluating the Geroprotective Effect of Metformin
Primary completion· ClinicalTrials.gov
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Primary completion· ClinicalTrials.gov
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Trial started· ClinicalTrials.gov
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
Primary completion· ClinicalTrials.gov
Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation
Primary completion· ClinicalTrials.gov
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Primary completion· ClinicalTrials.gov
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedion
Primary completion· ClinicalTrials.gov
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Primary completion· ClinicalTrials.gov
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Primary completion· ClinicalTrials.gov
Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
Primary completion· ClinicalTrials.gov
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
Primary completion· ClinicalTrials.gov
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Primary completion· ClinicalTrials.gov
Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
Primary completion· ClinicalTrials.gov
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Primary completion· ClinicalTrials.gov
Dapagliflozin in Depression
Primary completion· ClinicalTrials.gov
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
Primary completion· ClinicalTrials.gov
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Past events
2026
Results posted· ClinicalTrials.gov
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
INDICATIONS AND USAGE Glipizide and metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accom
Label revision· FDA
WARNING: LACTIC ACIDOSIS Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accom
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accom
Label revision· FDA
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accomp
Label revision· FDA
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accomp
Results posted· ClinicalTrials.gov
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
Trial registered· ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Primary completion· ClinicalTrials.gov
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Trial started· ClinicalTrials.gov
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prosta
Trial started· ClinicalTrials.gov
Dapagliflozin in Active Lupus Nephritis
Primary completion· ClinicalTrials.gov
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
Primary completion· ClinicalTrials.gov
The Effect of Dapagliflozin on Patients With Cardiomyopathy
Primary completion· ClinicalTrials.gov
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
Trial registered· ClinicalTrials.gov
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablet is indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial registered· ClinicalTrials.gov
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Primary completion· ClinicalTrials.gov
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Trial registered· ClinicalTrials.gov
Krill Oil and Metformin in Women With PCOS and Metabolically Unhealthy Obesity
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often
Label revision· FDA
Boxed warning present on label on glyburide and metformin hydrochloride label (effective 2026-05-21)
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
Label revision· FDA
Boxed warning present on label on glyburide and metformin hydrochloride label (effective 2026-05-21)
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
FDA approval (supplemental)· FDA
Sponsor: SUN PHARM. Class: Manufacturing (CMC).
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial registered· ClinicalTrials.gov
DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Ty
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk facto
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk facto
Trial registered· ClinicalTrials.gov
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk facto
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk facto
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accom
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
Boxed warning present on label on Glyburide and Metformin Hydrochloride label (effective 2026-05-07)
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
Boxed warning present on label on Glyburide and Metformin Hydrochloride label (effective 2026-05-07)
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompa
Label revision· FDA
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accom
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
Primary completion· ClinicalTrials.gov
Finerenone Plus SGLT2 Inhibitors in Heart Failure
Trial started· ClinicalTrials.gov
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
Trial started· ClinicalTrials.gov
Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department
Primary completion· ClinicalTrials.gov
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Trial started· ClinicalTrials.gov
Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragm
Primary completion· ClinicalTrials.gov
The Fontan Dapagliflozin Pilot Study
Primary completion· ClinicalTrials.gov
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Primary completion· ClinicalTrials.gov
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Trial registered· ClinicalTrials.gov
Dapagliflozin in Living-Donor Kidney Transplant Recipients
Trial registered· ClinicalTrials.gov
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Trial started· ClinicalTrials.gov
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Results posted· ClinicalTrials.gov
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
Trial registered· ClinicalTrials.gov
A Randomised Controlled Trial to Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aorti
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial started· ClinicalTrials.gov
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Trial registered· ClinicalTrials.gov
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablet is indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors
Trial registered· ClinicalTrials.gov
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
FDA approval· FDA
Sponsor: ALKEM LABS LTD.
FDA approval· FDA
Sponsor: MSN.
FDA approval· FDA
Sponsor: LUPIN.
FDA approval· FDA
Sponsor: SUN PHARM.
FDA approval· FDA
Sponsor: AUROBINDO PHARMA.
FDA approval· FDA
Sponsor: TEVA PHARMS USA.
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk facto
FDA approval· FDA
Sponsor: ALKEM LABS LTD.
FDA approval· FDA
Sponsor: ALEMBIC.
FDA approval· FDA
Sponsor: MSN.
FDA approval· FDA
Sponsor: AJANTA PHARMA LTD.
FDA approval· FDA
Sponsor: MACLEODS PHARMS LTD.
FDA approval· FDA
Sponsor: ZYDUS PHARMS.
FDA approval· FDA
Sponsor: SANDOZ.
FDA approval· FDA
Sponsor: AUROBINDO PHARMA.
FDA approval· FDA
Sponsor: AIZANT.
FDA approval· FDA
Sponsor: BIOCON PHARMA.
FDA approval· FDA
Sponsor: INVENTIA.
FDA approval· FDA
Sponsor: LUPIN.
FDA approval· FDA
Sponsor: MACLEODS PHARMS LTD.
FDA approval· FDA
Sponsor: CIPLA.
FDA approval· FDA
Sponsor: MSN.
Primary completion· ClinicalTrials.gov
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
Label revision· FDA
1 INDICATIONS AND USAGE Dapagliflozin is indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. As an
Trial started· ClinicalTrials.gov
Dapagliflozin for Long COVID Syndrome
Trial started· ClinicalTrials.gov
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Primary completion· ClinicalTrials.gov
Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema
Primary completion· ClinicalTrials.gov
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
Results posted· ClinicalTrials.gov
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Trial registered· ClinicalTrials.gov
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Trial registered· ClinicalTrials.gov
Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
Trial started· ClinicalTrials.gov
POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
Trial registered· ClinicalTrials.gov
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accom
Primary completion· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body
Trial registered· ClinicalTrials.gov
POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
Primary completion· ClinicalTrials.gov
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
Trial started· ClinicalTrials.gov
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
Trial started· ClinicalTrials.gov
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic So
Primary completion· ClinicalTrials.gov
Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
Trial started· ClinicalTrials.gov
The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure
Trial started· ClinicalTrials.gov
Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia
Primary completion· ClinicalTrials.gov
A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metform
Trial registered· ClinicalTrials.gov
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Trial started· ClinicalTrials.gov
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Primary completion· ClinicalTrials.gov
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
Trial started· ClinicalTrials.gov
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
Primary completion· ClinicalTrials.gov
Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Trial registered· ClinicalTrials.gov
The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure
Results posted· ClinicalTrials.gov
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial registered· ClinicalTrials.gov
A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metform
Trial registered· ClinicalTrials.gov
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
Trial registered· ClinicalTrials.gov
Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department
Trial started· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body
Trial started· ClinicalTrials.gov
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Mida
Trial registered· ClinicalTrials.gov
Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia
Primary completion· ClinicalTrials.gov
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
Trial registered· ClinicalTrials.gov
Metformin vs Inositol vs Diet vs Combination Therapy in PCOS
Primary completion· ClinicalTrials.gov
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic C
Trial started· ClinicalTrials.gov
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Primary completion· ClinicalTrials.gov
Triple Therapy in T1DM
Primary completion· ClinicalTrials.gov
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
Trial started· ClinicalTrials.gov
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Primary completion· ClinicalTrials.gov
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Primary completion· ClinicalTrials.gov
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Results posted· ClinicalTrials.gov
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Results posted· ClinicalTrials.gov
Anti-Diabetic Medications to Fight PD and LBD
Trial registered· ClinicalTrials.gov
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in F
Trial registered· ClinicalTrials.gov
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Mida
Trial registered· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body
Trial registered· ClinicalTrials.gov
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
Results posted· ClinicalTrials.gov
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Trial registered· ClinicalTrials.gov
Finerenone Plus SGLT2 Inhibitors in Heart Failure
Trial registered· ClinicalTrials.gov
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Trial started· ClinicalTrials.gov
Finerenone Plus SGLT2 Inhibitors in Heart Failure
Trial registered· ClinicalTrials.gov
Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragm
Trial registered· ClinicalTrials.gov
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial registered· ClinicalTrials.gov
Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Dis
Primary completion· ClinicalTrials.gov
Dapagliflozin in Pulmonary Arterial Hypertension
Trial registered· ClinicalTrials.gov
A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is
Trial registered· ClinicalTrials.gov
Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation
Results posted· ClinicalTrials.gov
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furo
Trial started· ClinicalTrials.gov
A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metform
Trial registered· ClinicalTrials.gov
Dapagliflozin in Active Lupus Nephritis
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle, accomp
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accomp
Trial started· ClinicalTrials.gov
Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation
2025
Primary completion· ClinicalTrials.gov
DANHEART (H-HeFT and Met-HeFT)
Trial registered· ClinicalTrials.gov
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus a
Primary completion· ClinicalTrials.gov
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Primary completion· ClinicalTrials.gov
Dapagliflozin in Allo-HCT for aGVHD
Trial registered· ClinicalTrials.gov
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prosta
Trial started· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Primary completion· ClinicalTrials.gov
Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis
Trial started· ClinicalTrials.gov
Epicardial Cardiac Fat-CT (EPIC-CT)
Primary completion· ClinicalTrials.gov
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in F
Primary completion· ClinicalTrials.gov
A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Plac
Trial registered· ClinicalTrials.gov
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
Label revision· FDA
INDICATIONS & USAGE Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Trial started· ClinicalTrials.gov
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus a
Trial registered· ClinicalTrials.gov
Epicardial Cardiac Fat-CT (EPIC-CT)
Primary completion· ClinicalTrials.gov
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Trial registered· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Trial registered· ClinicalTrials.gov
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic So
Label revision· FDA
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accom
Trial started· ClinicalTrials.gov
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Trial registered· ClinicalTrials.gov
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Primary completion· ClinicalTrials.gov
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patient
Results posted· ClinicalTrials.gov
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Trial registered· ClinicalTrials.gov
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
Primary completion· ClinicalTrials.gov
Metformin and Nightly Fasting in Women With Early Breast Cancer
Label revision· FDA
INDICATIONS & USAGE Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Trial started· ClinicalTrials.gov
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Particip
Trial registered· ClinicalTrials.gov
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.